Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more
Merus BV (MRUS) - Net Assets
Latest net assets as of September 2025: $661.63 Million USD
Based on the latest financial reports, Merus BV (MRUS) has net assets worth $661.63 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($771.99 Million) and total liabilities ($110.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $661.63 Million |
| % of Total Assets | 85.7% |
| Annual Growth Rate | 45.37% |
| 5-Year Change | 535.97% |
| 10-Year Change | 2001.84% |
| Growth Volatility | 81.82 |
Merus BV - Net Assets Trend (2012–2024)
This chart illustrates how Merus BV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Merus BV (2012–2024)
The table below shows the annual net assets of Merus BV from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $650.36 Million | +82.51% |
| 2023-12-31 | $356.34 Million | +44.24% |
| 2022-12-31 | $247.06 Million | -21.87% |
| 2021-12-31 | $316.20 Million | +209.20% |
| 2020-12-31 | $102.26 Million | -22.12% |
| 2019-12-31 | $131.30 Million | +24.94% |
| 2018-12-31 | $105.09 Million | +82.93% |
| 2017-12-31 | $57.45 Million | +60.52% |
| 2016-12-31 | $35.79 Million | +15.67% |
| 2015-12-31 | $30.94 Million | +814.98% |
| 2014-12-31 | $-4.33 Million | -140.90% |
| 2013-12-31 | $10.58 Million | +44.94% |
| 2012-12-31 | $7.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Merus BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 94968491200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.96 Million | 1.07% |
| Other Comprehensive Income | $-55.47 Million | -8.56% |
| Other Components | $1.66 Billion | 256.95% |
| Total Equity | $647.93 Million | 100.00% |
Merus BV Competitors by Market Cap
The table below lists competitors of Merus BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zoomlion Heavy Industry Science and Technology Co Ltd
SHE:000157
|
$6.31 Billion |
|
Compeq Manufacturing Co Ltd
TW:2313
|
$6.31 Billion |
|
Amdocs Limited
F:AOS
|
$6.31 Billion |
|
EL PUERTO LIVER.N.-VTG.C1
F:PLV1
|
$6.31 Billion |
|
BYD CO.LTD SDR/0,10 O.N.
F:4BY1
|
$6.30 Billion |
|
Aker BP ASA
PINK:AKRBF
|
$6.29 Billion |
|
Summit Materials Inc
NYSE:SUM
|
$6.29 Billion |
|
APA Group
PINK:APAJF
|
$6.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Merus BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 356,343,000 to 647,927,000, a change of 291,584,000 (81.8%).
- Net loss of 207,854,187 reduced equity.
- New share issuances of 457,476,000 increased equity.
- Other comprehensive income decreased equity by 32,932,000.
- Other factors increased equity by 74,894,187.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-207.85 Million | -32.08% |
| Share Issuances | $457.48 Million | +70.61% |
| Other Comprehensive Income | $-32.93 Million | -5.08% |
| Other Changes | $74.89 Million | +11.56% |
| Total Change | $- | 81.83% |
Book Value vs Market Value Analysis
This analysis compares Merus BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.75x to 8.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $3.96 | $90.00 | x |
| 2014-12-31 | $-0.28 | $90.00 | x |
| 2015-12-31 | $2.01 | $90.00 | x |
| 2016-12-31 | $2.71 | $90.00 | x |
| 2017-12-31 | $2.99 | $90.00 | x |
| 2018-12-31 | $4.72 | $90.00 | x |
| 2019-12-31 | $5.42 | $90.00 | x |
| 2020-12-31 | $3.50 | $90.00 | x |
| 2021-12-31 | $8.18 | $90.00 | x |
| 2022-12-31 | $5.50 | $90.00 | x |
| 2023-12-31 | $6.91 | $90.00 | x |
| 2024-12-31 | $10.09 | $90.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Merus BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -595.93%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.21x
- Recent ROE (-32.08%) is above the historical average (-56.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -93.65% | -1775.63% | 0.03x | 1.62x | $-10.97 Million |
| 2014 | 0.00% | -1336.07% | 0.30x | 0.00x | $-16.98 Million |
| 2015 | -75.16% | -1220.79% | 0.05x | 1.25x | $-26.35 Million |
| 2016 | -132.54% | -1889.92% | 0.03x | 2.12x | $-51.02 Million |
| 2017 | -112.75% | -295.57% | 0.09x | 4.11x | $-70.52 Million |
| 2018 | -23.51% | -73.77% | 0.13x | 2.38x | $-35.22 Million |
| 2019 | -37.45% | -177.15% | 0.11x | 2.01x | $-62.30 Million |
| 2020 | -68.45% | -285.59% | 0.11x | 2.26x | $-80.23 Million |
| 2021 | -18.57% | -136.06% | 0.09x | 1.44x | $-90.32 Million |
| 2022 | -49.59% | -315.48% | 0.10x | 1.52x | $-147.23 Million |
| 2023 | -39.38% | -352.56% | 0.09x | 1.28x | $-175.98 Million |
| 2024 | -32.08% | -595.93% | 0.04x | 1.21x | $-272.65 Million |
Industry Comparison
This section compares Merus BV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Merus BV (MRUS) | $661.63 Million | -93.65% | 0.17x | $6.30 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |